(Q27000514)

A. Collins

2

1 reference

M. K. Oehler

3

1 reference

A. Zippelius

4

1 reference

V. A. Heinzelmann-Schwarz

5

1 reference

language of work or name

1 reference

February 2014

1 reference

1 reference

25

1 reference

PubMed

issue

2

1 reference

PubMed

page(s)

322-31

1 reference

PubMed

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Treatment for recurrent ovarian cancer-at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

The therapeutic use of rituximab in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Monoclonal antibodies as therapeutic agents for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Role of monoclonal antibodies in tumor-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

The suppressive tumor microenvironment: a challenge in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Chemotherapy and tumor immunity: an unexpected collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Chemoimmunotherapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

Mucinous tumours of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405

A step further in understanding the biology of the folate receptor in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT405